Vedolizumab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
NICE (England), NYE METODER (Norway) and PHARMAC (New Zealand), among others, recommended or restricted vedolizumab, while CIPM (Spain) did not recommend it.
HAS (France) has been harder on vedolizumab than on its own caseload: it refused 3 of 5 decisive submissions here (60%), against a base rate of 11% across everything it has assessed.
Assessment has run over 11.9 years, from 4 Apr 2014 at AWMSG (Wales) to 3 Mar 2026 at PHARMAC (New Zealand).
CONITEC (Brazil) changed its position: not recommended on 27 May 2019, recommended by 13 May 2025, after a resubmission.
Every one of the eight highest-volume agencies in this archive has a record for vedolizumab.
Not every gap is a refusal: for vedolizumab, 1 submission was never made and 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 7 of 44 records date from 2023 or later.
The programme is broad: 14 distinct indication wordings are recorded for vedolizumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
7 of these 44 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess vedolizumab, on 4 Apr 2014; CIPM (Spain) did not open a file until 28 Oct 2021 — a wide spread of 7.5 years between the earliest and latest system to look at it.
The record arrives in waves: 10 separate years each carry two or more decisions, spread across 10 years in total.
11 of the 12 agencies here assessed vedolizumab more than once, PBAC (Australia) most often at 7 entries — repeat review is the norm for this molecule rather than the exception.
vedolizumab has been through 12 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for vedolizumab reads 19 recommended, 9 not recommended, 7 restricted and 3 other, with 6 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PHARMAC (New Zealand) | 3 Mar 2026 | Ulcerative colitis and Crohn's disease, secondary loss of response to vedolizumab (dose escalation) | PTAC advice: No Formal Recommendation | source |
| PBAC (Australia) | 2025 | Severe Crohn disease (CD)Moderate to severe ulcerative colitis (MSUC) | Not Recommended | source |
| CONITEC (Brazil) | 13 May 2025 | Tratamento da doença de Crohn moderada a grave ativa após falha, intolerância ou contraindicação a um anti-TNF. | incorporated into SUS | source |
| NYE METODER (Norway) | 27 Apr 2025 | Behandling av voksne med pouchitt, som har gjennomgått proktokolektomi med ileoanalt bekkenreservoar (IPAA) ved ulcerøs … | decision recorded | source |
| HAS (France) | 19 Oct 2022 | Indication extension | SMR insufficient | source |
39 further decisions for vedolizumab, across 12 agencies, are not shown here. They include the most recent record on file, 3 Mar 2026 from PHARMAC (New Zealand); its outcome is in the subscriber dataset. They link to 27 further source documents.
Related molecules
- adalimumab — same ATC class L04A — Immunosuppressants
- upadacitinib — same ATC class L04A — Immunosuppressants
- secukinumab — same ATC class L04A — Immunosuppressants
- tocilizumab — same ATC class L04A — Immunosuppressants
- ustekinumab — same ATC class L04A — Immunosuppressants
- infliximab — same ATC class L04A — Immunosuppressants
Coverage: 44 decisions for vedolizumab from 12 agencies, 2014 to 2026. Data to 7 Sep 2026. ATC class L04A — Immunosuppressants. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.